My Sell call on Moderna ( MRNA ) in April 2025 had looked a little bold at the time, given the extent of correction and perception of lack of room to correct further. So I will takeI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, stress testin ...